# Real-World Scientific Examples (Curated)

This document provides a curated set of practical examples demonstrating how to combine the available Claude RCDD Skills to solve real scientific problems. These examples have been adapted to the current toolset.

---

## 📋 Table of Contents


### Drug Discovery - Computational Workflows
1. [Drug Discovery: Discovery of Novel EGFR Inhibitors](#drug-discovery-discovery-of-novel-egfr-inhibitors)
2. [Drug Discovery: Drug Repurposing for Rare Diseases](#drug-discovery-drug-repurposing-for-rare-diseases)
3. [Drug Discovery: Structure-Based Design of PPI Inhibitors](#drug-discovery-structure-based-design-of-protein-protein-interaction-inhibitors)
4. [Drug Discovery: Target Identification and Validation for a Natural Product](#drug-discovery-target-identification-and-validation-for-a-natural-product)

### Literature Review & Research Workflows
5. [Literature Review: Systematic Target Validation for Drug Discovery](#literature-review-systematic-target-validation-for-drug-discovery)
6. [Literature Review: Critical Evaluation of Clinical Trial Evidence](#literature-review-critical-evaluation-of-clinical-trial-evidence)
7. [Literature Review: Hypothesis Generation from Natural Product Studies](#literature-review-hypothesis-generation-from-natural-product-studies)
8. [Literature Review: Pre-Project Assessment of a Novel Drug Target](#literature-review-pre-project-assessment-of-a-novel-drug-target)

---

## Drug Discovery: Discovery of Novel EGFR Inhibitors

**Objective**: Identify novel small molecule inhibitors of the Epidermal Growth Factor Receptor (EGFR) with improved properties compared to existing drugs, potentially overcoming known resistance mutations.

**Skills Used**:
- `chembl-database` - Query bioactivity data for known inhibitors.
- `pubchem-database` - Search for compound information and commercial availability.
- `rdkit` - Analyze molecular properties and generate chemical analogs.
- `medchem` - Predict drug-likeness and ADMET properties.
- `pdb-database` - Retrieve predicted protein structures for docking.
- `pubmed-database` & `literature-review` - Gather information on resistance mutations and prior art.
- `opentargets-database` - Validate targets and find mutation data.
- `scientific-visualization` - Create figures and reports.
- `zinc-database` - Provides context for molecular docking tools like AutoDock.

**Workflow**:

```bash
# Workflow for discovering novel EGFR inhibitors.

# Step 1: Query ChEMBL for known EGFR inhibitors with high potency.
# - Search for compounds targeting EGFR (CHEMBL203).
# - Filter for high potency (e.g., IC50 < 50 nM).
# - Extract SMILES strings and activity data into a working dataset.

# Step 2: Analyze structure-activity relationships with RDKit.
# - Load compounds into RDKit.
# - Calculate key molecular descriptors (MW, LogP, TPSA, HBD, HBA).
# - Generate fingerprints to identify common chemical scaffolds among the most potent inhibitors.

# Step 3: Identify key resistance mutations.
# - Use 'opentargets-database' and a 'literature-review' on PubMed to find clinically relevant EGFR mutations in lung cancer (e.g., T790M, C797S).
# - This information is crucial for designing next-generation inhibitors.

# Step 4: Retrieve EGFR protein structure.
# - Download the predicted structure of the EGFR kinase domain from the 'pdb-database'.
# - If available, also retrieve an experimental structure from the PDB for comparison.
# - Prepare the structure for docking by adding hydrogens and optimizing its geometry.

# Step 5: Generate novel analogs with RDKit.
# - Based on the top scaffolds identified in Step 2, use RDKit's chemical transformation functions to generate a library of novel, virtual analogs.
# - Filter this new library for drug-likeness using Lipinski's Rule of Five.

# Step 6: Predict properties of new analogs.
# - Use the 'medchem' and 'rdkit' skills to predict ADMET properties (solubility, permeability, toxicity alerts) for the virtual library.
# - Rank candidates based on predicted potency and favorable drug-like properties.

# Step 7: Perform virtual screening via molecular docking.
# - Select the top 50-100 candidates for docking.
# - Perform molecular docking against both the wild-type and mutant EGFR structures using a tool like AutoDock (as referenced in the 'zinc-database' skill).
# - Analyze the resulting binding poses and calculated binding energies.

# Step 8: Check for commercial availability.
# - For the top 10 candidates from docking, use their chemical identifiers (like InChI keys) to search 'pubchem-database' for commercial suppliers.

# Step 9: Conduct final literature validation.
# - Use the 'literature-review' skill on PubMed to search for any prior publications or patents related to the top-ranking scaffolds to ensure novelty.

# Step 10: Create a comprehensive report.
# - Use 'scientific-visualization' to generate 2D structure images, scatter plots of properties (e.g., MW vs. LogP), and visualizations of the best docking poses.
# - Write a scientific summary of the methodology, results, and recommendations for which compounds to synthesize and test experimentally.

# ---
# Expected Output: A ranked list of 10-20 novel EGFR inhibitor candidates with predicted activity, favorable ADMET properties, and strong docking scores against wild-type and mutant EGFR. The output should be a comprehensive report ready for review.
```

---

## Drug Discovery: Drug Repurposing for Rare Diseases

**Objective**: Identify existing FDA-approved drugs that could be repurposed for treating a rare metabolic disorder by analyzing their targets and pathways.

**Skills Used**:
- `drugbank-database` - Query for approved drugs and their targets.
- `opentargets-database` - Find and validate target-disease associations.
- `string-database` - Analyze protein-protein interaction networks.
- `reactome-database` & `reactome-database` - Perform pathway analysis.
- `pubmed-database` & `literature-review` - Find data on trials and drug safety.
- `scientific-visualization` - Create network and pathway diagrams.

**Workflow**:

```bash
# Workflow for identifying drug repurposing candidates for a rare disease.

# Step 1: Define the disease pathway.
# - Query the 'reactome-database' and 'reactome-database' for pathways associated with the rare metabolic disorder.
# - Identify the key proteins and enzymes involved in the disease pathophysiology.

# Step 2: Build and analyze a protein-protein interaction (PPI) network.
# - Use the key disease proteins from Step 1 to query the 'string-database' for known interaction partners.
# - Conceptually analyze the resulting PPI network to identify highly connected "hub" proteins that could be effective drug targets.

# Step 3: Identify druggable targets.
# - Query the 'opentargets-database' for the key proteins in the disease pathway to assess their "druggability" and clinical precedence.
# - Prioritize targets that are known to be modulated by existing approved drugs.

# Step 4: Find drugs that hit the prioritized targets.
# - Search the 'drugbank-database' for all approved drugs that act on the high-priority targets identified in the previous step.
# - Retrieve the mechanism of action and safety information for these drugs.

# Step 5: Investigate drug safety and clinical trial history.
# - Use the 'literature-review' skill to search 'pubmed-database' for safety data, adverse events, and black box warnings for the candidate drugs.
# - Concurrently, search for any past or ongoing clinical trials related to repurposing these drugs for any disease, which might reveal potential issues or opportunities.

# Step 6: Perform pathway enrichment analysis.
# - Map the targets of the candidate drugs back to the disease pathways from Step 1.
# - Identify drugs that affect multiple nodes or key control points in the disease pathway.

# Step 7: Conduct a final systematic literature review.
# - Use the 'literature-review' skill to find any direct or indirect evidence (e.g., case reports, preclinical studies) linking the candidate drugs to the rare disease.

# Step 8: Prioritize and report candidates.
# - Rank the candidates based on the strength of the pathway linkage, existing safety profile, and any supporting evidence from the literature.
# - Use 'scientific-visualization' to create a diagram illustrating the drug-target-pathway relationships.
# - Generate a detailed report summarizing the evidence for the top 5 candidates and recommend next steps for preclinical validation.

# ---
# Expected Output: A ranked list of 5-10 high-potential repurposing candidates, supported by a comprehensive report with network analysis, safety evidence, and a clear rationale for each.
```

---

## Drug Discovery: Structure-Based Design of Protein-Protein Interaction (PPI) Inhibitors

**Objective**: Computationally design novel small molecules that are predicted to disrupt a therapeutically relevant protein-protein interaction (PPI).

**Skills Used**:
- `pdb-database` & `pdb-database` - Retrieve protein structures.
- `uniprot-database` - Get functional information and annotations for the proteins.
- `biopython` - Analyze protein structures and identify the interaction interface.
- `zinc-database` - Find commercially available compounds for virtual screening.
- `rdkit` & `medchem` - Generate and filter chemical libraries and predict properties.
- `pubmed-database` - Conduct literature and patent searches.
- `scientific-writing` - Prepare the final design report.

**Workflow**:

```bash
# Workflow for designing inhibitors of a protein-protein interaction.

# Step 1: Retrieve protein structures.
# - Download the structures of the two interacting proteins from 'pdb-database' or, if available, 'pdb-database' for experimental structures.

# Step 2: Analyze the PPI interface.
# - Use 'biopython' to load the structures and identify the interface residues (e.g., residues on each protein within 5 angstroms of the other).
# - Identify "hot spot" residues that are key for the binding interaction.

# Step 3: Characterize the binding pocket.
# - Analyze the surface topology at the interface to find druggable pockets or grooves.
# - Note the properties of these pockets (e.g., hydrophobicity, depth) to guide molecule design.

# Step 4: Search for a screening library.
# - Query the 'zinc-database' for a library of purchasable, lead-like compounds suitable for screening against PPI targets.

# Step 5: Perform virtual screening.
# - Dock the library of compounds from ZINC into the identified binding pockets on the protein surface using a docking program like AutoDock or Glide.
# - Rank the compounds based on their predicted binding affinity and how well they interact with the hot spot residues.

# Step 6: Elaborate on promising hits.
# - Select the top-ranking fragments or "hits" from the initial screen.
# - Use 'rdkit' to generate a new, more focused library of virtual compounds by modifying and growing these initial hits.

# Step 7: Predict ADMET properties.
# - Use the 'medchem' and 'rdkit' skills to predict the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) properties of the newly designed molecules.
# - Filter out any molecules with predicted liabilities (e.g., high toxicity, poor solubility).

# Step 8: Perform a final round of docking.
# - Dock the refined and filtered library of designed molecules back into the protein target to get a final binding prediction.
# - Rank the final candidates based on a combined score of binding affinity and favorable ADMET properties.

# Step 9: Conduct literature and patent search.
# - Use 'pubmed-database' to search for any existing patents or publications on similar chemical scaffolds targeting this PPI to ensure novelty.

# Step 10: Generate a comprehensive design report.
# - Use 'scientific-writing' and 'scientific-visualization' to create a report detailing the design process.
# - Include visualizations of the top 10 designed molecules, their predicted binding poses, and their predicted properties.
# - Provide a final recommendation for which 3-5 compounds should be prioritized for synthesis and experimental testing.

# ---
# Expected Output: A list of 5-10 novel, synthetically feasible PPI inhibitor candidates with strong predicted binding affinity, favorable ADMET properties, and supporting data presented in a professional report.
```
---

## Drug Discovery: Target Identification and Validation for a Natural Product

**Objective**: To investigate the potential biological targets of the natural product Hesperidin, validate the most promising target through computational analysis, and assess its therapeutic potential.

**Skills Used**:
- `pubmed-database` & `literature-review` - Gather existing knowledge on the compound.
- `pubchem-database` - Retrieve compound structures and bioactivity data.
- `rdkit` - Perform chemical similarity searches.
- `chembl-database` - Find similar molecules with known bioactivities.
- `opentargets-database` - Identify and prioritize potential biological targets.
- `string-database` - Analyze protein-protein interaction networks.
- `reactome-database` - Evaluate biological pathways associated with targets.
- `pdb-database` & `pdb-database` - Retrieve 3D protein structures for analysis.
- `scientific-visualization` & `scientific-writing` - Report and visualize findings.
- **External Tools**: Schrödinger Suite (Glide for docking, FEP+ for ABFE).

**Workflow**:

```bash
# Workflow for identifying and validating a biological target for a natural product.

# Step 1: Initial Data Mining on Hesperidin.
# - Use 'pubchem-database' to obtain the canonical SMILES structure for Hesperidin.
# - Conduct a 'literature-review' on 'pubmed-database' to find all existing research on Hesperidin, looking for mentions of its effects on protein expression, cellular pathways, or disease models.

# Step 2: Analog Search and Target Hypothesis Generation.
# - Use the SMILES of Hesperidin with 'rdkit' to conduct a similarity search in the 'chembl-database'.
# - This identifies molecules with similar structures that have known, annotated biological targets, providing initial hypotheses.
# - Use this list of molecules and Hesperidin to query 'opentargets-database' to build a list of potential protein targets.

# Step 3: Target Prioritization using Network and Pathway Analysis.
# - Input the list of potential targets from Open Targets into the 'string-database' to visualize their protein-protein interaction network. Identify any "hub" proteins that connect multiple potential targets.
# - Use the 'reactome-database' to perform pathway enrichment analysis on the target list to see if they cluster in specific signaling or metabolic pathways.
# - Prioritize a single, promising target based on its network centrality, pathway relevance, and the strength of evidence from the literature review.

# Step 4: Retrieve Protein Structure for Docking.
# - For the prioritized target (e.g., Target X), search for an experimental high-resolution crystal structure in the 'pdb-database'.
# - If no experimental structure is available, retrieve a high-quality predicted structure from the 'pdb-database'.

# Step 5: Molecular Docking with Schrödinger Glide (External Tool).
# - Prepare the protein structure and the Hesperidin ligand for docking.
# - **(External)** Perform molecular docking using the Glide program from the Schrödinger Suite to predict the binding pose and calculate the docking score.
# - Analyze the pose to ensure key interactions (e.g., hydrogen bonds, hydrophobic contacts) are formed.

# Step 6: Verify Binding Affinity with ABFE (External Tool).
# - For the most promising docked pose, perform a more rigorous binding energy calculation.
# - **(External)** Use a tool like FEP+ from the Schrödinger Suite to run an Absolute Binding Free Energy (ABFE) simulation, providing a more accurate prediction of the binding affinity (ΔG).

# Step 7: Synthesize Findings in a Report.
# - Use 'scientific-writing' to compile all findings into a cohesive report.
# - Include visualizations of the chemical similarity search, the protein interaction network from STRING, and the final docking pose.
# - The report should present a clear hypothesis for Hesperidin's mechanism of action, supported by literature, pathway analysis, and computational chemistry results.

# ---
# Expected Output: A comprehensive report that proposes a primary biological target for Hesperidin, supported by literature, pathway/network analysis, a high-confidence docking pose, and a robust binding free energy prediction from advanced simulation.
```
---

## Literature Review: Systematic Target Validation for Drug Discovery

**Objective**: Conduct a systematic literature review to validate whether a protein target (e.g., PKM2 in cancer metabolism) has sufficient evidence to justify investment in a drug discovery program.

**Skills Used**:
- `pubmed-database` & `literature-review` - Comprehensive literature search and screening.
- `scientific-critical-thinking` - Evaluate study quality and evidence strength.
- `hypothesis-generation` - Identify mechanistic gaps and formulate testable hypotheses.
- `native statistical analysis` - Meta-analyze reported efficacy data across studies.
- `scientific-writing` - Prepare systematic review report with proper citations.
- `opentargets-database` - Cross-validate genetic evidence for target-disease association.
- `string-database` - Analyze target's biological context in pathway networks.
- `perplexity-search` - Find recent developments, preprints, and real-time data not yet in structured databases.

**Workflow**:
```bash
# Workflow for systematic target validation through literature review.

# Step 1: Define review scope and search strategy.
# - Clearly define the target protein (e.g., PKM2) and disease indication (e.g., non-small cell lung cancer).
# - Use 'scientific-critical-thinking' to formulate focused research questions:
#   * Is there robust genetic or functional evidence linking this target to disease pathogenesis?
#   * Have small molecule modulators shown efficacy in preclinical models?
#   * Are there validated biomarkers for target engagement?
#   * What are the known resistance mechanisms or safety concerns?

# Step 2: Conduct comprehensive literature search.
# - Use 'pubmed-database' with a structured search strategy:
#   * Primary search: "(PKM2 OR pyruvate kinase M2) AND (cancer OR tumor OR oncology)"
#   * Add filters: Last 10 years, English language, article types (original research, reviews, clinical trials)
#   * Document search date and number of results retrieved
# - Use 'literature-review' skill to systematically screen titles and abstracts
# - Use 'perplexity-search' to find recent papers, preprints, and conference abstracts that might be missed by standard PubMed searches
# - Apply inclusion criteria: studies with functional validation, drug efficacy data, or clinical evidence
# - Apply exclusion criteria: case reports, editorials, studies without mechanistic data

# Step 3: Cross-validate with genetic evidence databases.
# - Query 'opentargets-database' for PKM2-cancer associations
# - Check genetic evidence score, tractability assessment, and known drugs
# - Compare database evidence with literature findings to identify discrepancies

# Step 4: Extract and organize data from selected papers.
# - For each included study, systematically extract:
#   * Study design (in vitro, in vivo model, patient samples)
#   * Key findings (knockdown/knockout effects, drug treatment outcomes)
#   * Efficacy metrics (IC50 values, tumor growth inhibition, survival benefit)
#   * Methodological quality indicators (sample size, controls, statistical methods)
# - Organize data in a structured format for analysis

# Step 5: Critical quality assessment of studies.
# - Use 'scientific-critical-thinking' to evaluate each study:
#   * Assess experimental design rigor (appropriate controls, blinding, replication)
#   * Evaluate statistical methods and data presentation
#   * Identify potential biases (publication bias, conflicts of interest)
#   * Rate evidence strength (strong/moderate/weak based on study design and reproducibility)
# - Flag studies with methodological concerns or conflicting results

# Step 6: Synthesize evidence and perform meta-analysis.
# - Use 'native statistical analysis' to aggregate reported efficacy data:
#   * Calculate pooled effect sizes across preclinical studies (e.g., mean tumor growth inhibition)
#   * Assess heterogeneity between studies (I² statistic)
#   * Identify factors contributing to variability (model system, compound class, dosing)
# - Create summary statistics for key outcomes

# Step 7: Analyze biological context with network analysis.
# - Query 'string-database' with PKM2 to visualize its protein interaction network
# - Identify functionally related proteins and pathway connections
# - Use this context to assess target specificity and potential off-target effects
# - Evaluate whether the target is amenable to small molecule modulation based on network position

# Step 8: Identify knowledge gaps and generate hypotheses.
# - Use 'scientific-critical-thinking' to identify:
#   * Mechanistic gaps in understanding target-disease relationship
#   * Missing validation experiments (e.g., genetic validation in relevant models)
#   * Unexplored resistance mechanisms
# - Use 'hypothesis-generation' to formulate testable hypotheses:
#   * Propose experiments to fill critical gaps
#   * Suggest biomarker strategies for patient stratification
#   * Identify potential combination therapy approaches

# Step 9: Assess druggability and competitive landscape.
# - Search for existing chemical compounds targeting PKM2
# - Use 'perplexity-search' to find recent competitor announcements, press releases, or early disclosures
# - Evaluate whether sufficient chemical starting points exist or if novel chemistry is needed

# Step 10: Prepare comprehensive validation report.
# - Use 'scientific-writing' to compile findings into a structured report:
#   * Executive summary with go/no-go recommendation
#   * Systematic review methodology (following PRISMA guidelines)
#   * Evidence synthesis with supporting data tables and figures
#   * Critical assessment of evidence quality and gaps
#   * Recommended next steps for target progression
# - Format citations properly for internal report
# - Include decision criteria matrix (evidence strength, druggability, competitive position)

# ---
# Expected Output: A comprehensive target validation report with evidence-based recommendation on whether to initiate drug discovery efforts, supported by systematic literature analysis, statistical synthesis of efficacy data, and clear identification of knowledge gaps and experimental priorities.
```

---

## Literature Review: Critical Evaluation of Clinical Trial Evidence

**Objective**: Critically evaluate conflicting clinical trial results for a drug candidate to determine the true efficacy and safety profile, and provide an evidence-based recommendation for continued development.

**Skills Used**:
- `pubmed-database` & `literature-review` - Find and retrieve clinical trial publications.
- `peer-review` - Apply structured evaluation criteria to assess trial quality.
- `scholar-evaluation` - Systematically score research methodology and reporting quality.
- `scientific-critical-thinking` - Identify methodological flaws and biases.
- `native statistical analysis` - Reanalyze trial data and assess statistical validity.
- `hypothesis-generation` - Propose explanations for conflicting results.
- `scientific-writing` - Prepare evaluation report with APA citation style.

**Workflow**:
```bash
# Workflow for critical evaluation of conflicting clinical trial evidence.

# Step 1: Identify and retrieve all relevant clinical trials.
# - Use 'pubmed-database' to search for all published trials:
#   * Search: "(Drug X) AND (indication Y) AND (clinical trial[Publication Type] OR randomized controlled trial)"
#   * Include: Phase II and Phase III trials, both published and registered but unpublished
#   * Document: ClinicalTrials.gov registry numbers, publication status, funding sources
# - Use 'literature-review' to screen and categorize trials by:
#   * Phase (II vs. III)
#   * Design (RCT vs. single-arm)
#   * Primary endpoint achieved (yes/no)
#   * Publication status (peer-reviewed vs. conference abstract vs. unpublished)

# Step 2: Extract key trial characteristics and results.
# - For each trial, systematically extract:
#   * Study design: randomization method, blinding, control arm, sample size
#   * Patient population: inclusion/exclusion criteria, baseline characteristics, disease severity
#   * Intervention: dosing regimen, treatment duration, concomitant therapies
#   * Outcomes: primary and secondary endpoints, effect sizes with confidence intervals
#   * Statistical methods: analysis approach (ITT vs. per-protocol), handling of missing data
#   * Funding source and conflicts of interest
# - Create a standardized extraction table for comparison

# Step 3: Apply structured peer review criteria.
# - Use 'peer-review' skill to evaluate each trial on multiple dimensions:
#   * **Methodology Quality**: 
#     - Randomization adequacy (sequence generation, allocation concealment)
#     - Blinding implementation (participants, investigators, outcome assessors)
#     - Sample size justification and power calculation
#   * **Statistical Rigor**:
#     - Appropriateness of statistical tests
#     - Multiple comparison corrections
#     - Subgroup analysis pre-specification
#   * **Reporting Quality**:
#     - CONSORT guideline adherence
#     - Complete outcome reporting
#     - Transparency about protocol deviations
#   * **Ethical Standards**:
#     - Informed consent procedures
#     - Data monitoring committee oversight
#     - Stopping rules and interim analyses

# Step 4: Score trials using scholar evaluation framework.
# - Use 'scholar-evaluation' to assign quantitative scores:
#   * Problem formulation (5 points): Clear hypothesis, justified endpoints
#   * Methodology design (10 points): Rigorous randomization, appropriate controls
#   * Data collection (5 points): Complete follow-up, validated outcome measures
#   * Statistical analysis (10 points): Pre-specified plan, appropriate methods
#   * Results interpretation (5 points): Objective reporting, acknowledged limitations
#   * Overall quality score: Sum of components (max 35 points)
# - Classify trials as high-quality (≥28), moderate (20-27), or low-quality (<20)

# Step 5: Identify and analyze sources of heterogeneity.
# - Use 'scientific-critical-thinking' to systematically compare trials:
#   * **Patient Population Differences**:
#     - Disease severity (early vs. advanced stage)
#     - Prior treatment exposure (treatment-naive vs. heavily pretreated)
#     - Biomarker status (enriched vs. unselected populations)
#   * **Intervention Differences**:
#     - Dosing variations (mg/kg vs. flat dose, schedule differences)
#     - Treatment duration and dose modifications
#     - Combination therapy vs. monotherapy
#   * **Outcome Measurement Differences**:
#     - Endpoint definitions (PFS vs. OS, response criteria)
#     - Assessment timing and frequency
#     - Adjudication processes
# - Create a matrix comparing these factors across all trials

# Step 6: Perform quantitative analysis of effect sizes.
# - Use 'native statistical analysis' to meta-analyze results:
#   * Extract hazard ratios or risk ratios with 95% confidence intervals
#   * Calculate pooled effect estimate using random-effects model (accounting for heterogeneity)
#   * Perform sensitivity analysis excluding low-quality trials
#   * Assess publication bias using funnel plots and Egger's test
#   * Calculate I² statistic to quantify heterogeneity between trials
# - Perform subgroup meta-analyses to explore sources of heterogeneity:
#   * By patient population characteristics
#   * By intervention parameters
#   * By methodological quality score

# Step 7: Evaluate safety profile across trials.
# - Systematically compare adverse event reporting:
#   * Grade 3-4 adverse events (frequency and types)
#   * Treatment discontinuations due to toxicity
#   * Serious adverse events and deaths
# - Assess quality of safety reporting (completeness, grading consistency)
# - Identify safety signals that may explain efficacy differences (dose reductions affecting outcomes)

# Step 8: Generate hypotheses for conflicting results.
# - Use 'hypothesis-generation' to propose mechanistic explanations:
#   * Pharmacokinetic variability in different populations
#   * Biomarker-defined subgroups with differential response
#   * Drug-drug interactions in combination regimens
#   * Disease biology differences (acquired resistance mechanisms)
# - Formulate testable hypotheses for future studies:
#   * Propose biomarker-stratified trial designs
#   * Suggest PK/PD studies to optimize dosing
#   * Identify need for companion diagnostics

# Step 9: Assess reporting bias and conflicts of interest.
# - Use 'scientific-critical-thinking' to evaluate:
#   * Selective outcome reporting (comparing registered vs. published endpoints)
#   * Spin in conclusions (overstating positive findings, downplaying negative results)
#   * Industry funding influence on study design or interpretation
#   * Publication delays for negative trials (time-lag bias)
# - Check trial registries (ClinicalTrials.gov) for unpublished studies suggesting publication bias

# Step 10: Prepare comprehensive evaluation report with recommendations.
# - Use 'scientific-writing' to compile findings using APA citation style:
#   * **Executive Summary**: 
#     - Overall efficacy conclusion with strength of evidence rating
#     - Safety profile summary
#     - Go/No-go recommendation with conditions
#   * **Methods Section**:
#     - Literature search strategy
#     - Inclusion/exclusion criteria
#     - Quality assessment framework
#     - Statistical analysis methods
#   * **Results Section**:
#     - Individual trial summaries with quality scores
#     - Meta-analysis results with forest plots
#     - Heterogeneity analysis
#     - Safety synthesis
#   * **Critical Discussion**:
#     - Reconciliation of conflicting results
#     - Quality concerns and their impact on conclusions
#     - Hypotheses for discrepancies
#   * **Recommendations**:
#     - Evidence-based development decision
#     - Proposed confirmatory studies if needed
#     - Biomarker strategies or patient selection criteria
#   * **References**: 
#     - Format all citations in APA 7th edition style
#     - Example: "Smith, J. A., & Jones, B. C. (2023). Phase III trial of Drug X in advanced disease. *New England Journal of Medicine*, *388*(12), 1234-1245. https://doi.org/10.1056/NEJMoa123456"
# - Include supplementary materials: quality assessment scores, meta-analysis data, bias assessment

# ---
# Expected Output: A rigorous critical evaluation report that reconciles conflicting trial evidence, identifies methodological issues affecting interpretation, provides quantitative synthesis of effects, and delivers an evidence-based recommendation for drug development decisions. Report formatted with proper APA citations suitable for regulatory submission or internal decision-making.
```

---

## Literature Review: Hypothesis Generation from Natural Product Studies

**Objective**: Mine the natural product literature to identify promising bioactive compounds with underexplored therapeutic potential, analyze their structural features and reported activities, and generate novel hypotheses for drug discovery programs.

**Skills Used**:
- `pubmed-database` & `literature-review` - Comprehensive search of natural product literature.
- `scientific-brainstorming` - Generate creative connections and novel applications.
- `hypothesis-generation` - Formulate testable hypotheses for drug development.
- `scientific-critical-thinking` - Evaluate evidence quality and identify gaps.
- `pubchem-database` & `chembl-database` - Retrieve compound structures and bioactivity data.
- `rdkit` - Analyze structural features and identify scaffold families.
- `hmdb-database` - Check for endogenous metabolite status and physiological roles.
- `reactome-database` - Map compounds to metabolic pathways.
- `scientific-writing` - Document hypotheses and proposed research directions.

**Workflow**:
```bash
# Workflow for generating drug discovery hypotheses from natural product literature.

# Step 1: Identify a promising natural product class or source.
# - Use 'scientific-brainstorming' to select a focus area:
#   * Underexplored plant families with ethnobotanical use
#   * Marine natural products from specific taxa (e.g., sponges, tunicates)
#   * Microbial secondary metabolites from unusual environments
#   * Traditional medicine compounds with reported but unvalidated effects
# - Example focus: Triterpenoids from medicinal plants (e.g., betulinic acid, ursolic acid)

# Step 2: Conduct comprehensive literature search.
# - Use 'pubmed-database' with systematic search strategy:
#   * Primary search: "(triterpenoid OR triterpene) AND (medicinal plant OR traditional medicine)"
#   * Add biological activity terms: "AND (anticancer OR anti-inflammatory OR antiviral)"
#   * Time filter: Focus on last 15 years for recent biological insights
#   * Include both in vitro and in vivo studies
# - Use 'literature-review' to organize findings by:
#   * Compound class (ursane, oleanane, lupane skeletons)
#   * Reported biological activities
#   * Target organs/diseases
#   * Mechanistic insights (when available)

# Step 3: Extract and catalog bioactive natural products.
# - For each promising compound from literature:
#   * Extract chemical name, source organism, and structural information
#   * Query 'pubchem-database' to obtain canonical SMILES and InChI
#   * Document reported bioactivities with potency data (IC50, EC50 values)
#   * Note mechanistic information: proposed targets, pathway effects, phenotypic outcomes
# - Create a structured database with compounds, activities, and evidence quality ratings

# Step 4: Analyze structural features and identify patterns.
# - Use 'rdkit' to analyze the compound collection:
#   * Calculate molecular descriptors (MW, LogP, TPSA, flexibility)
#   * Generate molecular fingerprints for similarity analysis
#   * Identify common structural scaffolds and functional groups
#   * Perform substructure searches to find shared pharmacophores
# - Cluster compounds by structural similarity to identify compound families
# - Correlate structural features with reported bioactivities

# Step 5: Mine bioactivity databases for additional evidence.
# - Query 'chembl-database' for each natural product:
#   * Find additional bioassay data not reported in primary literature
#   * Identify confirmed protein targets with binding data
#   * Discover related synthetic analogs with improved properties
# - Compare literature-reported activities with database annotations
# - Identify discrepancies or gaps in target identification

# Step 6: Map compounds to biological pathways.
# - Query 'hmdb-database' to check if compounds are endogenous metabolites:
#   * Identify physiological roles and normal concentration ranges
#   * Understand biosynthetic pathways and metabolic fate
# - Use 'reactome-database' to map compounds to metabolic pathways:
#   * Identify pathway enrichment patterns (e.g., steroid metabolism, inflammation)
#   * Discover related metabolites and pathway connections
#   * Understand potential mechanism-of-action from pathway context

# Step 7: Identify knowledge gaps using critical analysis.
# - Use 'scientific-critical-thinking' to evaluate the evidence:
#   * **Mechanistic Gaps**: Which highly active compounds lack identified targets?
#   * **Selectivity Questions**: Are reported activities specific or due to general cytotoxicity?
#   * **Pharmacological Gaps**: Are ADMET properties characterized? Bioavailability data?
#   * **Clinical Translation Gaps**: Have any compounds advanced to clinical testing? Why or why not?
#   * **Structure-Activity Gaps**: Which structural modifications have/haven't been explored?
# - Prioritize compounds with strong activity but incomplete mechanistic understanding

# Step 8: Generate novel hypotheses through structured brainstorming.
# - Use 'scientific-brainstorming' to explore creative connections:
#   * **Cross-indication hypothesis**: "If Compound X inhibits inflammation in arthritis models, 
#     could it address neuroinflammation in Alzheimer's disease?"
#   * **Polypharmacology hypothesis**: "Given that Compound Y affects multiple kinases, 
#     could it be valuable in combination therapy for resistant cancers?"
#   * **Scaffold-hopping hypothesis**: "Can we replace the triterpenoid core with a simpler, 
#     synthetically accessible scaffold while retaining key pharmacophore elements?"
#   * **Prodrug hypothesis**: "Given poor bioavailability, could we design ester or glycoside 
#     prodrugs for improved oral absorption?"
# - Explore biomimetic synthesis routes for complex natural products

# Step 9: Formulate testable hypotheses with experimental plans.
# - Use 'hypothesis-generation' to develop structured research hypotheses:
#   * **Hypothesis 1 - Target Identification**:
#     - "Maslinic acid exerts anticancer effects through selective inhibition of Protein X"
#     - Proposed experiments: Target fishing, SPR binding assays, co-crystal structure
#   * **Hypothesis 2 - Structure Optimization**:
#     - "Simplification of the pentacyclic scaffold to a tricyclic core will retain activity 
#        while improving synthetic accessibility and ADMET properties"
#     - Proposed experiments: Design-make-test cycle with 20-30 analogs, SAR analysis
#   * **Hypothesis 3 - Mechanism-Based Combination**:
#     - "Natural product X synergizes with standard-of-care Drug Y through complementary 
#        pathway inhibition"
#     - Proposed experiments: Combination matrix screening, pathway analysis, xenograft studies
#   * **Hypothesis 4 - Biomarker-Driven Application**:
#     - "Natural product Z is selectively active in tumors with Biomarker B expression"
#     - Proposed experiments: Biomarker profiling of cell lines, patient sample correlation

# Step 10: Prioritize and document research opportunities.
# - Rank hypotheses based on:
#   * Strength of preliminary evidence from literature
#   * Feasibility (synthetic accessibility, assay availability)
#   * Commercial potential (unmet need, competitive landscape)
#   * Biosens capabilities and expertise alignment
# - Use 'scientific-writing' to create a comprehensive hypothesis document:
#   * **Executive Summary**: Top 3 prioritized hypotheses with one-line rationales
#   * **Background**: Literature synthesis establishing the opportunity
#   * **Detailed Hypotheses**: Each with supporting evidence, proposed experiments, success criteria
#   * **Resource Requirements**: Chemistry FTE, biology assays, external services needed
#   * **Timeline and Milestones**: 12-24 month development plan
#   * **Risk Assessment**: Technical risks, competitive risks, mitigation strategies
#   * **References**: Complete bibliography of supporting literature

# ---
# Expected Output: A portfolio of 3-5 well-supported, testable hypotheses for natural product-based drug discovery programs, each with clear mechanistic rationale, experimental validation plans, and assessment of development feasibility. Document serves as foundation for project initiation and resource allocation decisions at Biosens.
```

---

## Literature Review: Pre-Project Assessment of a Novel Drug Target

**Objective**: Conduct comprehensive due diligence on a novel therapeutic target before initiating a drug discovery program, integrating evidence from genetics, literature, protein structure, pathway biology, and competitive landscape to make a go/no-go decision.

**Skills Used**:
- `pubmed-database` & `literature-review` - Comprehensive literature mining and evidence synthesis.
- `opentargets-database` - Genetic evidence and target-disease associations.
- `uniprot-database` - Protein function, domains, and isoform information.
- `string-database` - Protein interaction networks and functional context.
- `reactome-database` & `reactome-database` - Pathway analysis and biological context.
- `pdb-database` & `pdb-database` - Structural assessment of druggability.
- `chembl-database` & `drugbank-database` - Existing chemical matter and competitive intelligence.
- `scientific-critical-thinking` - Rigorous evaluation of evidence strength and quality.
- `hypothesis-generation` - Identify key validation experiments and development strategies.
- `native statistical analysis` - Quantitative assessment of genetic evidence and literature trends.
- `scientific-visualization` - Create comprehensive assessment figures and dashboards.
- `scientific-writing` - Prepare decision-ready target assessment report.
- `perplexity-search` - Conduct rapid competitive intelligence and find latest industry news.

**Workflow**:
```bash
# Workflow for comprehensive pre-project target assessment.

# Step 1: Define target and therapeutic hypothesis.
# - Clearly articulate the target protein (e.g., Novel Kinase X)
# - Define the disease indication (e.g., inflammatory bowel disease)
# - State the therapeutic hypothesis: "Inhibition of Kinase X will reduce inflammatory 
#   signaling in intestinal epithelial cells, leading to disease remission"
# - Document the source of this hypothesis (phenotypic screen, genetic study, competitor program)

# Step 2: Gather comprehensive genetic evidence.
# - Query 'opentargets-database' for target-disease associations:
#   * Overall association score (0-1 scale)
#   * Genetic evidence score from GWAS, rare variant studies
#   * Somatic mutation evidence (for oncology targets)
#   * Animal model phenotypes
#   * Affected pathway information
# - Use 'scientific-critical-thinking' to assess genetic evidence strength:
#   * Are associations replicated across multiple studies?
#   * What is the effect size and statistical significance?
#   * Is there evidence of causality or just correlation?
#   * Are there relevant human genetic knockout models or loss-of-function variants?

# Step 3: Conduct systematic literature review of target biology.
# - Use 'pubmed-database' with comprehensive search strategy:
#   * Target name and aliases: "(Kinase X OR Gene Symbol OR Protein Name)"
#   * Disease context: "AND (inflammatory bowel disease OR ulcerative colitis OR Crohn's disease)"
#   * Mechanistic terms: "AND (inflammation OR immune response OR epithelial barrier)"
#   * Temporal scope: Last 10 years for recent insights, expand if sparse literature
# - Use 'literature-review' to systematically categorize publications:
#   * Functional studies: What does the target do at molecular level?
#   * Disease association: Epidemiological or clinical evidence
#   * Model systems: In vitro, in vivo validation of target role
#   * Clinical biomarkers: Expression in patient samples, correlation with disease severity
# - Use 'perplexity-search' to find recent high-impact papers, news, or industry reports not yet indexed
# - Extract key evidence metrics: number of publications per year, citation patterns, funding sources

# Step 4: Analyze protein structure and function.
# - Query 'uniprot-database' for comprehensive protein annotation:
#   * Full-length sequence and molecular weight
#   * Domain architecture (catalytic domains, regulatory domains)
#   * Known isoforms and splice variants
#   * Post-translational modifications (phosphorylation sites, glycosylation)
#   * Tissue expression patterns and subcellular localization
#   * Known protein-protein interactions
# - Query 'pdb-database' for experimental structures:
#   * Check for crystal structures of target or close homologs
#   * Assess resolution quality and ligand-bound states
#   * Identify binding site characteristics
# - If no experimental structure, query 'pdb-database':
#   * Retrieve predicted structure with confidence scores
#   * Assess structural druggability of predicted binding sites
#   * Note regions with low confidence that might affect drug design

# Step 5: Map target to biological networks and pathways.
# - Query 'string-database' with target protein:
#   * Generate protein-protein interaction network
#   * Identify direct interaction partners (confidence scores)
#   * Assess network position: Is target a hub or peripheral node?
#   * Identify functional modules and pathway context
# - Use 'reactome-database' to map target to signaling pathways:
#   * Identify all pathways containing the target
#   * Determine target's position (upstream regulator vs. downstream effector)
#   * Find pathway crosstalk and redundancy issues
# - Use 'reactome-database' for detailed pathway analysis:
#   * Visualize target in pathway diagrams
#   * Identify downstream effectors that could serve as pharmacodynamic biomarkers
#   * Assess potential compensatory pathways
# - Use 'scientific-critical-thinking' to evaluate targetability:
#   * Is the target in a non-redundant pathway position?
#   * Are there parallel pathways that could compensate for target inhibition?
#   * Does network analysis support or challenge the therapeutic hypothesis?

# Step 6: Assess structural druggability.
# - Analyze protein structure for drug binding sites:
#   * Evaluate size, shape, and chemical properties of potential binding pockets
#   * Assess accessibility and flexibility of binding sites
#   * Identify key residues for structure-based drug design
# - Consider target class precedent:
#   * For kinases: Is ATP site suitable for inhibitor binding? Allosteric sites available?
#   * For protein-protein interactions: Are interface hot spots druggable?
#   * For enzymes: Is active site chemically tractable?
# - Rate structural druggability: High/Medium/Low with supporting rationale

# Step 7: Conduct competitive intelligence and freedom-to-operate analysis.
# - Query 'chembl-database' for existing chemical matter:
#   * Search for compounds with reported activity against the target
#   * Analyze chemical scaffolds and potency ranges
#   * Identify tool compounds for validation studies
# - Query 'drugbank-database' for approved or clinical-stage drugs:
#   * Check if any drugs already target this protein
#   * Identify drugs targeting closely related family members
#   * Assess mechanism-of-action overlap
# - Use 'literature-review' to search patent literature:
#   * Identify active competitors and their chemistry IP
#   * Assess novelty space available for Biosens program
#   * Note any composition-of-matter patents that could block development
# - Search 'pubmed-database' for clinical trial publications:
#   * Have competitors advanced any programs to clinic?
#   * What were the outcomes (efficacy, safety, discontinued programs)?
#   * Are there learnings about target validation or patient selection?
# - Use 'perplexity-search' to find recent patent filings, company pipelines, and clinical trial updates

# Step 8: Identify critical knowledge gaps and validation needs.
# - Use 'scientific-critical-thinking' to systematically identify gaps:
#   * **Mechanism Gaps**: Is MOA fully understood? Substrate/pathway clarity?
#   * **Genetic Validation**: Are there human LOF variants? Knockout model phenotypes?
#   * **Pharmacological Validation**: Have tool compounds confirmed target role?
#   * **Biomarker Gaps**: How will target engagement be measured? PD markers identified?
#   * **Safety Concerns**: Any toxicity signals from genetic/preclinical data?
#   * **Patient Selection**: Are there biomarkers to identify responsive patients?
# - Use 'hypothesis-generation' to propose critical experiments:
#   * Genetic validation: CRISPR knockout in disease-relevant cell models
#   * Chemical validation: Test tool inhibitors in phenotypic assays
#   * Biomarker development: Develop target engagement and PD biomarker assays
#   * Patient stratification: Analyze target expression in patient cohorts

# Step 9: Quantitative synthesis and risk assessment.
# - Use 'native statistical analysis' to quantify evidence:
#   * Meta-analyze effect sizes from genetic association studies
#   * Calculate publication trends (papers/year) as proxy for field maturity
#   * Score evidence strength using weighted criteria:
#     - Genetic evidence (30%): GWAS significance, human knockout data
#     - Functional validation (25%): In vitro and in vivo model data
#     - Clinical evidence (20%): Biomarker correlations, patient sample data
#     - Structural druggability (15%): Binding site quality, tool compounds
#     - Competitive position (10%): Freedom-to-operate, differentiation potential
#   * Generate overall target attractiveness score (0-100 scale)
# - Perform risk assessment:
#   * **Scientific Risk**: Strength of target validation, MOA clarity
#   * **Feasibility Risk**: Structural druggability, chemical starting points
#   * **Competitive Risk**: IP landscape, competitor programs
#   * **Commercial Risk**: Market size, reimbursement, clinical trial feasibility
# - Rate each risk dimension: Low/Medium/High with mitigation strategies

# Step 10: Prepare comprehensive target assessment report.
# - Use 'scientific-visualization' to create:
#   * Evidence pyramid showing strength across genetic, functional, clinical data
#   * Protein interaction network with target highlighted in pathway context
#   * Timeline of publications and competitor activities
#   * Druggability assessment visualization (binding site analysis)
#   * Risk-opportunity matrix positioning this target vs. other programs
# - Use 'scientific-writing' to compile comprehensive report:
#   * **Executive Summary** (1 page):
#     - Go/No-go recommendation with confidence level
#     - Target attractiveness score and key supporting evidence
#     - Top 3 reasons to proceed and top 3 risks
#     - Proposed next steps and resource requirements
#   * **Target Biology Section**:
#     - Molecular function and pathway context
#     - Disease association evidence (genetic, clinical, preclinical)
#     - Expression patterns and cellular localization
#   * **Validation Evidence Section**:
#     - Genetic validation summary with effect sizes
#     - Functional validation from model systems
#     - Clinical/translational evidence from patient studies
#     - Quantitative evidence scoring with supporting data
#   * **Druggability Assessment Section**:
#     - Structural analysis of binding sites
#     - Target class precedent and chemical tractability
#     - Existing chemical matter and tool compounds
#     - Predicted challenges for chemistry campaign
#   * **Competitive Landscape Section**:
#     - Active competitors and their development stages
#     - IP landscape and freedom-to-operate assessment
#     - Differentiation opportunities for Biosens program
#   * **Knowledge Gaps and Validation Plan**:
#     - Critical experiments needed before program launch
#     - Biomarker development requirements
#     - Estimated timeline and cost for validation phase
#   * **Risk Assessment and Mitigation**:
#     - Detailed risk analysis across all dimensions
#     - Proposed mitigation strategies for each risk
#     - Go/No-go decision criteria and checkpoints
#   * **Recommendation and Next Steps**:
#     - Clear recommendation with supporting rationale
#     - If GO: Proposed program structure, team, budget, timeline
#     - If NO-GO: Alternative target suggestions or wait-for-data strategy
#   * **Comprehensive References**:
#     - Complete bibliography of all evidence sources
#     - Database query records for reproducibility

# ---
# Expected Output: A 20-30 page comprehensive target assessment report that synthesizes evidence from genetics, literature, structural biology, pathway analysis, and competitive intelligence to provide a data-driven recommendation on whether to initiate a drug discovery program. Report includes quantitative scoring, risk analysis, and clear next steps, ready for senior leadership review and investment decision.
```
